×

MDxHealth's ConfirmMDx Covered by Tufts Health Plan

IRVINE, Calif. and HERSTAL, Belgium, Sept. 17, 2015 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: MDXH.BR) announced that it has signed an agreement with Tufts Health Plan for their government and commercial programs/products. The agreement provides access to ConfirmMDx for Prostate Cancer testing for Tufts Health Plan's 1 million members.

Tufts Health Plan collaborates closely to develop its programs with the clinical professionals of Tufts Medical Center. As part of their world-class academic medical center, Tufts offers members the choice of top-ranked care, world-renowned innovation and the highest quality community providers, which it refers to as an "integrated delivery and financing system."

"MDxHealth is pleased to provide ConfirmMDx testing to Tufts' members, helping to improve patient outcomes and reduce the cost of care," said Dr. Jan Groen CEO of MDxHealth. "This agreement enables streamlined claims adjudication and reimbursement for the ConfirmMDx test on all eligible patients."

About Tufts Health Plan

Founded in 1979, Tufts Health Plan is nationally recognized for its commitment to providing innovative, high-quality health care coverage. Touching the lives of more than one million members, Tufts Health Plan serves members in Massachusetts, Rhode Island and New Hampshire, offering health care coverage regardless of age or circumstance.

About ConfirmMDx® for Prostate Cancer

Over 975,000 American men are diagnosed with a negative prostate biopsy each year; however approximately 25-35% of those men receive false-negative results. Under the current standard of care, prostate biopsy procedures consisting of 10-12 needle biopsy cores only sample approximately 1% of a man's prostate. This approach leaves men at risk of undetected cancer, leading to a high rate of repeat biopsies, even on cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level. This "halo" around a cancer lesion can be present despite cells having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying truly negative men who may forego an unnecessary repeat biopsy procedure. Performance of the proprietary ConfirmMDx genes and technology has been published in 45 studies on over 5,000 patients tested. The ConfirmMDx test has qualified for Medicare reimbursement as of November 3, 2014 and is also available to more than 152 million insured lives via private health insurance plans.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

For more information:



Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com








Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
Cell: + 44 7739658783
fennell@consilium-comms.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

To access the PDF version, click here http://hugin.info/137314/R/1952507/710191.pdf

HUG#1952507

Source: MdxHealth (TM)